A phase 1 safety trial using the exportin1 inhibitor XPO1 has recently been launched to investigate the safety and beneficial vs. the off-target effects of exportin-1 inhibition in ALS patients (193). Here, XPO1 is linked to amyotrophic lateral sclerosis.